AstraZeneca's durvalumab shown in trial to reduce risk of death from lung cancer

LONDON, May 12 (Reuters) - AstraZeneca's key immunotherapy drug durvalumab was shown to reduce the risk of stage III lung cancer worsening or causing death in a trial, the pharmaceutical company said on Friday.

by reutersCOMPANYNEWS via Endless Supplies .Biz - News